title: Fibrinogen receptor (GPIIb-IIIa) antagonists derived from 5,6-bicyclic templates. Amidinoindoles, amidinoindazoles, and amidinobenzofurans containing the N-alpha-sulfonamide carboxylic acid function as potent platelet aggregation inhibitors.
abstract: A series of highly potent and specific fibrinogen receptor antagonists have been discovered and optimized through structural modification of the novel amidinoindole and benzofuran compounds, I and II. Systematic linker optimization afforded the amidinobenzofuran-containing inhibitor 29, which displayed an IC50 value of 250 nM in platelet aggregation assays. Attempts to enhance activity by modification of the beta-position of the beta-alanyl carboxylate group of 29 had only a modest effect on inhibitory activity in aggregation assays. Analogues prepared to enhance the activity by conformational restriction were also found to be equally or less potent. In contrast, modification at the alpha-position of the beta-alanyl carboxylate group resulted in the identification of extremely potent and novel amidinobenzofuran-containing derivatives 46-49. Reexamination of 5,6-bicyclic aromatic nucleus led to the further identification of amidinoindole- and amidinoindazole-containing derivatives 53-55. These analogues, 46-49 and 53-55, exhibited potent in vitro activity with IC50 values of 25-65 nM in platelet aggregation assays and an IC50 value of 2 nM in fibrinogen binding assays and demonstrated a selectivity of > 50,000-fold for GPIIb-IIIa versus the most closely related integrin, the vitronectin receptor, alpha v beta 3.
authors.affiliation: COR Therapeutics, Inc., South San Francisco, California 94080, USA.
authors.forename: T
authors.initials: T
authors.lastname: Su
authors.forename: M A
authors.initials: MA
authors.lastname: Naughton
authors.forename: M S
authors.initials: MS
authors.lastname: Smyth
authors.forename: J W
authors.initials: JW
authors.lastname: Rose
authors.forename: A E
authors.initials: AE
authors.lastname: Arfsten
authors.forename: J R
authors.initials: JR
authors.lastname: McCowan
authors.forename: J A
authors.initials: JA
authors.lastname: Jakubowski
authors.forename: V L
authors.initials: VL
authors.lastname: Wyss
authors.forename: K J
authors.initials: KJ
authors.lastname: Ruterbories
authors.forename: D J
authors.initials: DJ
authors.lastname: Sall
authors.forename: R M
authors.initials: RM
authors.lastname: Scarborough
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001572:Benzofurans / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D005340:Fibrinogen / Q000378:metabolism; D006801:Humans; D007191:Indazoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D015394:Molecular Structure; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011355:Prodrugs / Q000138:chemical synthesis / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D019030:Receptors, Vitronectin / Q000378:metabolism; D013449:Sulfonamides / Q000032:analysis; D019096:Vitronectin / Q000378:metabolism
chemical_list: D001572:Benzofurans; D007191:Indazoles; D007211:Indoles; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D011355:Prodrugs; D019030:Receptors, Vitronectin; D013449:Sulfonamides; D019096:Vitronectin; D005340:Fibrinogen